Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Medication Global Market Opportunities and Strategies to 2030: COVID 19 Impact and Recovery” report has been…
Ocular Therapeutix has dosed the first patient in phase 1 clinical trial of OTX-CSI for the treatment of dry eye…
Kala Pharmaceuticals has resubmitted its New Drug Application to the FDA for Eysuvis, its product candidate to treat dry eye disease.
Statistical Significance Not Achieved for Primary or Secondary Endpoints Due to High Rates of Disease Resolution in Vehicle-Treated Patients, but Activity of Reproxalap Observed to be Consistently Greater than Vehicle
Sun Pharma with its subsidiaries agrees to buy 100% of Ocular Technologies